Regeneron Reports Results of REGEN-COV Antibody Cocktail Used as Passive Vaccine to Prevent COVID-19

January 27, 2021 Auto Bot antibody, Clinical Trials, Prevent, REGEN-COV, Regeneron, Report, results 0

Shots:

  • The ongoing P-III trial involves assessing REGEN-COV (casirivimab & imdevimab) in 2000+ participants used as a passive vaccine to prevent COVID-19. An exploratory analysis, conducted on the first ~400 individuals, randomized to receive passive vaccination with REGEN-COV (1200mg, SC) vs PBO
  • Reduction in overall infections seen within 1st week with 100% prevention of symptomatic infections, 50% lower overall rates of infection and decreased peak virus levels and duration of viral shedding in asymptomatic infections
  • The confirmatory P-III results are expected early in Q2’21. REGEN-COV is being studied in two hospitalized patient trials and a P-III study for non-hospitalized patients

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: CNBC

The post Regeneron Reports Results of REGEN-COV Antibody Cocktail Used as Passive Vaccine to Prevent COVID-19 first appeared on PharmaShots.